Li, J.; Arest, S.; Olszowy, B.; Gordon, J.; Barrero, C.A.; Perez-Leal, O.
CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease. Antioxidants 2023, 12, 1363.
https://doi.org/10.3390/antiox12071363
AMA Style
Li J, Arest S, Olszowy B, Gordon J, Barrero CA, Perez-Leal O.
CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease. Antioxidants. 2023; 12(7):1363.
https://doi.org/10.3390/antiox12071363
Chicago/Turabian Style
Li, James, Sandra Arest, Bartlomiej Olszowy, John Gordon, Carlos A. Barrero, and Oscar Perez-Leal.
2023. "CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease" Antioxidants 12, no. 7: 1363.
https://doi.org/10.3390/antiox12071363
APA Style
Li, J., Arest, S., Olszowy, B., Gordon, J., Barrero, C. A., & Perez-Leal, O.
(2023). CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease. Antioxidants, 12(7), 1363.
https://doi.org/10.3390/antiox12071363
